On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...

JPMorgan pointed out that IL-33 was never a key component of its model, though. The company stressed that, even without accounting for any pipeline contribution, Dupixent, Eylea, and Regeneron ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while maintaining an Overweight rating on the stock. The revision follows what the ...

The disappointing guidance spurred a downgrade at JPMorgan. - Regeneron Pharmaceuticals (REGN) shares slump after Wells Fargo Securities cut the recommendation on Regeneron Pharmaceuticals Inc. to ...

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies. Latest U.S.

Regeneron purchased the pioneering company for $256 million at bankruptcy auction with the intent of using its genomic data to fuel drug discovery, the company said in a Monday statement.

Regeneron's co-founder, Dr. George D. Yancopoulos, who is also the company's president and chief scientific officer, described the 23andMe acquisition as part of Regeneron's strategy to use DNA ...

Regeneron Pharmaceuticals, which garnered attention in 2020 when President Donald Trump touted the company's experimental COVID-19 vaccine as a "cure," said Monday, May 19, that it will buy ...

Regeneron Pharmaceuticals said it will acquire "substantially all" of 23andMe's assets. The genetic testing company filed for Chapter 11 bankruptcy protection in March.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.